These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 6872413)

  • 1. Dose proportionality of amrinone.
    Edelson J; Park GB; Angellotti J; Kershner RP; Ryan JJ; McMahon FG
    Clin Pharmacol Ther; 1983 Aug; 34(2):190-4. PubMed ID: 6872413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bioavailability and intravenous pharmacokinetics of amrinone in humans.
    Park GB; Kershner RP; Angellotti J; Williams RL; Benet LZ; Edelson J
    J Pharm Sci; 1983 Jul; 72(7):817-9. PubMed ID: 6886991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amrinone metabolism.
    Kullberg MP; Freeman GB; Biddlecome C; Alousi AA; Edelson J
    Clin Pharmacol Ther; 1981 Mar; 29(3):394-401. PubMed ID: 7471610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the bipyridines amrinone and milrinone.
    Edelson J; Stroshane R; Benziger DP; Cody R; Benotti J; Hood WB; Chatterjee K; Luczkowec C; Krebs C; Schwartz R
    Circulation; 1986 Mar; 73(3 Pt 2):III145-52. PubMed ID: 3510771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between amrinone plasma concentration and cardiac index.
    Edelson J; LeJemtel TH; Alousi AA; Biddlecome CE; Maskin CS; Sonnenblick EH
    Clin Pharmacol Ther; 1981 Jun; 29(6):723-8. PubMed ID: 7226703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the acetylator phenotype on amrinone pharmacokinetics.
    Hamilton RA; Kowalsky SF; Wright EM; Cernak P; Benziger DP; Stroshane RM; Edelson J
    Clin Pharmacol Ther; 1986 Dec; 40(6):615-9. PubMed ID: 3780123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related amrinone pharmacokinetics in a pediatric population.
    Allen-Webb EM; Ross MP; Pappas JB; McGough EC; Banner W
    Crit Care Med; 1994 Jun; 22(6):1016-24. PubMed ID: 8205809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects.
    Eason CT; Usansky JI; Henry GP; Powles P; Bonner FW
    Eur J Drug Metab Pharmacokinet; 1988; 13(2):129-33. PubMed ID: 3145204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-related cardiovascular effects of amrinone during enflurane anesthesia in the dog.
    Makela VH; Kapur PA
    Anesth Analg; 1986 Aug; 65(8):849-52. PubMed ID: 3729021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Dec; 26(6):468-502. PubMed ID: 6360634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug.
    Hermiller JB; Leithe ME; Magorien RD; Unverferth DV; Leier CV
    J Pharmacol Exp Ther; 1984 Feb; 228(2):319-26. PubMed ID: 6694112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental and clinical pharmacokinetics of amrinone].
    Padrini R; Miglioli PA; Casiglia E; Piovan D; Ferrari M
    Cardiologia; 1982; 27(1):103-6. PubMed ID: 6927443
    [No Abstract]   [Full Text] [Related]  

  • 13. Isotretinoin kinetics after 80 to 320 mg oral doses.
    Colburn WA; Gibson DM
    Clin Pharmacol Ther; 1985 Apr; 37(4):411-4. PubMed ID: 3856501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology.
    Wilson H; Rocci ML; Weber KT; Andrews V; Likoff MJ
    Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):3-19. PubMed ID: 3589153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption kinetics of orally administered leucovorin calcium.
    McGuire BW; Sia LL; Haynes JD; Kisicki JC; Gutierrez ML; Stokstad EL
    NCI Monogr; 1987; (5):47-56. PubMed ID: 3501546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of intravenous and oral amrinone in patients with severe heart failure: relationship between intravenous and oral administration.
    LeJemtel TH; Keung EC; Schwartz WJ; Maskin CS; Greenberg MA; Davis RS; Forman R; Ribner HS; Sonnenblick EH
    Trans Assoc Am Physicians; 1979; 92():325-33. PubMed ID: 549256
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of amrinone on cardiac function, oxygen consumption and lactate production of an isolated, perfused, working guinea-pig heart.
    Zannad F; Juillere Y; Royer RJ
    Arch Int Pharmacodyn Ther; 1983 Jun; 263(2):264-71. PubMed ID: 6882099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amrinone: a promising new cardiotonic agent in the treatment of chronic cardiac failure.
    Likoff MJ; Weber KT; Andrews V; Janicki JS
    Herz; 1983 Aug; 8(4):199-205. PubMed ID: 6413341
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro electrophysiologic properties of amrinone in mammalian cardiac tissue.
    Piwonka RW; Canniff PC; Farah AE
    J Cardiovasc Pharmacol; 1983; 5(6):1058-67. PubMed ID: 6196555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.